Product image of Ilomedin (Iloprost Trometamol) supplied by GNH India

Ilomedin

Active Ingredient:
Iloprost Trometamol
Origin:
EU

Ilomedin (Iloprost Trometamol)

Iloprost Trometamol, the active ingredient in Ilomedin, is a prostacyclin analog presented as an intravenous solution for intravenous use. It is employed in the management of pulmonary arterial hypertension, digital ulcers linked to systemic sclerosis, and peripheral arterial disease in adult patients.

GNH India supplies Ilomedin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution. GNH India also offers temperature‑controlled logistics to maintain product integrity during shipment.

Manufacturer / TM Owner

Bayer Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Ilomedin (iloprost trometamol) acts on the prostacyclin pathway to treat severe vascular disorders.
  • Pulmonary arterial hypertension: improves exercise capacity and reduces pulmonary vascular resistance.
  • Digital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces new ulcer formation.
  • Peripheral arterial disease: enhances limb perfusion and may alleviate ischemic symptoms.

How It Works

  • Iloprost trometamol selectively binds to the IP (prostacyclin) receptor on vascular smooth‑muscle cells, activating adenylate cyclase and increasing intracellular cyclic‑AMP. The rise in cAMP leads to potent vasodilation of pulmonary and systemic arteries and inhibits platelet aggregation, thereby lowering pulmonary arterial pressure and improving microvascular blood flow. It also exerts anti‑inflammatory effects by modulating endothelial cell function and reduces smooth‑muscle proliferation, contributing to long‑term vascular remodeling control.

Side Effects

Ilomedin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Headache: mild to moderate throbbing pain.
  • Flushing: transient redness of the face or upper body.
  • Nausea: occasional upset stomach.
  • Jaw pain: discomfort during chewing.
  • Hypotension: mild drop in blood pressure during infusion.

Serious or Rare Side Effects

  • Severe hypotension: marked blood pressure fall requiring intervention.
  • Pulmonary edema: fluid accumulation in the lungs.
  • Bleeding complications: increased risk of hemorrhage.
  • Anaphylactic reaction: severe allergic response with airway compromise.

Precautions & Warnings

Prior to initiating Ilomedin therapy, clinicians should observe several precautionary measures to ensure patient safety.

  • Monitor blood pressure: check regularly during and after infusion.
  • Assess bleeding risk: avoid in patients with active hemorrhage or severe coagulopathy.
  • Use caution in renal impairment: adjust monitoring and consider dose modification.
  • Avoid concurrent potent vasodilators: may precipitate profound hypotension.
  • Pregnancy: safety not established; weigh potential benefits against risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ilomedin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Concomitant use with other potent vasodilators: may cause severe hypotension.
  • Anticoagulants (e.g., warfarin, heparin): increased risk of bleeding.
  • Epoprostenol or other prostacyclin analogs: additive vasodilatory effect.

Moderate Interactions (Monitor Closely)

  • Calcium channel blockers: may enhance hypotensive response.
  • Beta‑blockers: can affect hemodynamic stability.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce prostacyclin‑mediated vasodilation.

Frequently Asked Questions

Ilomedin is indicated for the treatment of pulmonary arterial hypertension, digital ulcers associated with systemic sclerosis, and peripheral arterial disease. In each case, the drug helps improve blood flow by dilating affected vessels and reducing platelet aggregation.

Iloprost Trometamol is a selective agonist of the IP (prostacyclin) receptor. Activation of this receptor raises intracellular cyclic‑AMP, causing vasodilation of pulmonary and systemic arteries and inhibiting platelet aggregation, which together lower pulmonary arterial pressure and improve tissue perfusion.

The dosing regimen for Ilomedin is individualized. A qualified prescriber determines the infusion rate, concentration, and duration based on the patient’s clinical condition, response, and tolerance. Specific dosing information should be obtained from the prescribing physician.

Safety data for Ilomedin in pregnancy and lactation are limited. The product’s pregnancy category is unknown, and it should only be used when the potential benefit justifies any possible risk to the fetus. Breastfeeding mothers should consult their healthcare provider before use.

To order Ilomedin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Ilomedin (iloprost) is a synthetic prostacyclin analog administered intravenously, whereas alternatives such as epoprostenol are also IV but have different stability and dosing profiles. Iloprost’s selective IP‑receptor activity may offer a slightly different side‑effect spectrum, and its formulation allows for controlled infusion rates.

Ilomedin should be stored refrigerated at 2‑8 °C. Keep the solution in its original container, protect it from light, and avoid freezing or shaking. If the product must be transported, maintain the cold chain to preserve potency.

Ilomedin is given as an intravenous infusion. The solution is diluted according to the prescriber’s instructions and administered over a prescribed period, typically under continuous monitoring of vital signs, especially blood pressure, to detect any acute reactions.

Serious risks include severe hypotension, pulmonary edema, significant bleeding, and rare anaphylactic reactions. Patients should be closely observed during infusion, and any signs of rapid blood‑pressure decline, respiratory distress, or allergic response require immediate medical intervention.

Ilomedin is contraindicated in patients with known hypersensitivity to iloprost or any formulation component, in those with active severe bleeding, and in individuals with uncontrolled severe hypotension. Caution is also advised for patients with severe renal impairment or unstable cardiac conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Iloprost Trometamol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT